SCHEMBL515890

SCHEMBL515890

C=CCCCC(=O)OC(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.55
ALDH1A1 P00352 4/20 0.53
FAAH O00519 7/20 0.50
MGLL Q99685 4/20 0.50
TSHR P16473 1/20 0.42
MAPT P10636 3/20 0.41
ABCC4 O15439 1/20 0.41
USP2 O75604 1/20 0.39
CYP3A4 P08684 1/20 0.39
RECQL P46063 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HPGD P15428 1/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
PGR P06401 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
ADRA2C P18825 1/20 0.38
SLC6A2 P23975 1/20 0.38
HTR2B P41595 1/20 0.38
MC3R P41968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL514945 0.94 LMNA (0.61) LMNAALDH1A1FAAHMGLLTSHR
SCHEMBL3112597 0.92 LMNA (0.65) LMNAALDH1A1FAAHMGLLTSHR
SCHEMBL8430088 0.92 LMNA (0.65) LMNAALDH1A1FAAHMGLLTSHR
SCHEMBL515320 0.92 LMNA (0.65) LMNAALDH1A1FAAHMGLLTSHR
SCHEMBL515404 0.92 LMNA (0.65) LMNAALDH1A1FAAHMGLLTSHR
SCHEMBL3122706 0.92 LMNA (0.65) LMNAALDH1A1FAAHMGLLTSHR
SCHEMBL3117003 0.92 LMNA (0.65) LMNAALDH1A1FAAHMGLLTSHR
SCHEMBL514518 0.88 FAAH (0.49) LMNAALDH1A1FAAHMGLLTSHR
SCHEMBL27707452 0.82 LMNA (0.57) LMNAALDH1A1FAAHTSHRMAPT
SCHEMBL28068569 0.81 LMNA (0.42) LMNAALDH1A1FAAHMGLLTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877958-B2 Method to prepare beta-functionalized aliphatic esters COGNIS IP MANAGEMENT GMBH (DE) 2014-11-04 US disclosed
EP-2274266-B1 PROCESS FOR THE PREPARATION OF PROSTAGLANDIN ANALOGUES AND INTERMEDIATES THEREOF SCINOPHARM TAIWAN LTD (TW) 2014-10-15 EP disclosed
CN-102369173-B Method for producing high-purity terminal olefin compound KURARAY CO 2014-09-10 CN disclosed
EP-2415740-B1 METHOD FOR PRODUCING HIGH-PURITY TERMINAL OLEFIN COMPOUND KURARAY CO (JP) 2013-12-25 EP disclosed
US-8609886-B2 Method for producing high purity terminal olefin compound KURARAY CO., LTD. (JP) 2013-12-17 US disclosed
US-20130225852-A1 Method To Prepare beta-Functionalized Aliphatic Esters COGNIS IP MANAGEMENT GMBH (DE) 2013-08-29 US disclosed
CN-102369173-A Method for producing high-purity terminal olefin compound KURARAY CO 2012-03-07 CN disclosed
EP-2415740-A1 METHOD FOR PRODUCING HIGH-PURITY TERMINAL OLEFIN COMPOUND Kuraray Co., Ltd. (JP) 2012-02-08 EP disclosed
US-20120029229-A1 METHOD FOR PRODUCING HIGH PURITY TERMINAL OLEFIN COMPOUND KURARAY CO., LTD. (JP) 2012-02-02 US disclosed
US-7714087-B2 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS, INC. (JP) 2010-05-11 US disclosed
CN-100357330-C Polar group-containing olefin copolymer, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS INC (JP) 2007-12-26 CN disclosed
CN-100335509-C Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS INC (JP) 2007-09-05 CN disclosed
EP-1734061-A2 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer and uses thereof MITSUI CHEMICALS, INC. (JP) 2006-12-20 EP disclosed
CN-1737016-A Polar group-containing olefin copolymer, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS INC (JP) 2006-02-22 CN disclosed
CN-1737017-A Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS INC (JP) 2006-02-22 CN disclosed
CN-1219800-C Polar group-containing olefin copolymer, thermoplastic resin composition containing the same, and use thereof MITSUI CHEMICALS INC (JP) 2005-09-21 CN disclosed
US-20040122192-A1 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS, INC. 2004-06-24 US disclosed
US-20020156207-A1 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS, INC. (JP) 2002-10-24 US disclosed
CN-1342715-A Polar group-containing olefin copolymer, process for producing the same, thermoplastic resin composition containing the same, and use thereof MITSUI CHEMICALS INC (JP) 2002-04-03 CN disclosed
EP-1186619-A2 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition contaning the copolymer, and uses thereof Mitsui Chemicals, Inc. (JP) 2002-03-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225852-A1 Method To Prepare beta-Functionalized Aliphatic Esters CYP8B1, EBP, DBH LMNA 1241/4885ALDH1A1 327/4885FAAH 201/4885
US-20120029229-A1 METHOD FOR PRODUCING HIGH PURITY TERMINAL OLEFIN COMPOUND ADH1A, ADH1C, OSBP LMNA 3696/4885ALDH1A1 233/4885FAAH 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.